|
Literatura
1. Groschel DHM, Hornick RB. Who introduced typhoid vaccination:
Almoth Wright or Richard Pfeiffer? Rev Infect Dis 3:1251- 1254, 1981.
2. Pfeiffer R, Kolle W. Experimentelle Untersuchungen zur Frage de Schutzimpfung
des Menschen gegen Typhus abdominalis [Experimental investigations on
the question of human immunization against Typhus abdominalis]. Deutsche
medizinische Wochenschrift. 1896;22:735-737.
3. Landy M. Enhancement of the immunogenicity of typhoid vaccine by retention
of the Vi antigen. Am J Hyg 58:148-164, 1953.
4. Walter Reed Army Institute of Research, International Laboratory for
Biological Standards SS. Physical and chemical studies on two dried inactivated
typhoid vaccines (vaccine K and L). Bull World Health Organ 30:647-652,
1964.
5. Wong KH, Feeley JC, Northrup RS, et al. Vi antigen from Salmonella
typhosa and immunity against typhoid fever: I. Isolation and immunologic
properties in animals. Infect Immun 9:348-353, 1974.
6. Robbins J, Robbins J. Reexamination of the protective role of the capsular
polysaccharide Vi antigen of Salmonella typhi. J Infect Dis 150:436-449,
1984.
7. Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus:
III. Preparation and immunochemical properties of the group A, group B
and group C meningococcal polysaccharides. Exp Med 129:1349-1365, 1969.
8. Germanier R, Furer E. Isolation and characterization of gal E mutant
Ty21a of Salmonella typhi: A candidate strain for a live oral typhoid
vaccine. J Infect Dis 141:553-558, 1975.
9. Gilman R, Hornick R, Woodward W, et al. Immunity in typhoid fever:
Evaluation of Ty21a-An epimeraseless mutant of S. typhi as a live oral
vaccine. J Infect Dis 136:717-723, 1977.
10. Levine MM, Ferreccio C, Black RE, et al. Progress in vaccines against
typhoid fever. Rev Infect Dis ll(suppl 3):S552-S567, 1989.
11. Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of
Ty21a live oral typhoid vaccine in enteric-coated capsule formulation.
Lancet 1:1049-1052, 1987.
12. Hirschel B, Wuthrich R, Somain B, et al. Inefficacy of the commercial
live oral Ty21a vaccine in the prevention of typhoid fever. Eur J Clin
Microbiol 4:295-298, 1985.
13. Benenson AS. Serological responses of man to typhoid vaccines. Bull
World Health Organ 30:653-662, 1964.
14. Yugoslav Typhoid Commission. Field and laboratory studies with typhoid
vaccines. Bull World Health Organ 16:897-910, 1957.
15. Ashcroft MT, Morrison-Ritchie J, Nicholson CC. Controlled field trial
in British Guyana schoolchildren of heat-killed-phenolized and acetone-killed
lyophilized typhoid vaccines. Am J Hyg 79:196-206, 1964.
16. Wahdan MH, Sippel JE, Mikhail EA. Controlled field trial of a typhoid
vaccine prepared with non-motile mutant of Salmonella typhi Ty2. Bull
World Health Organ 52:69-73, 1975.
17. Hone DM, Tacket C, Harris A, et al. Evaluation in volunteers of a
candidate live oral attenuated S,. typhi vector vaccine. J Clin Invest
90:1-9, 1992.
18. Levine MM, Herrington D, Murphy JR, et al. Safety, infectivity, immunogenicity
and in vivo stability of two attenuated auxotrophic mutant strains of
Salmandla typhi, 541Ty and 543Ty, as live oral vaccines in man. J Clin
Invest 79:888-902, 1987.
19. Tacket CO, Hone DM, Losonsky GA, et al. Clinical acceptability and
immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10:443-446,
1992.
20. Tacket CO, Sztein MB, Losonsky GA, et al. Safety and immune response
in humans of live oral Salmonella typhi vaccine strains deleted in htrA
and aroC, aroD. Infect Immun 65:452-456, 1997.
21. Tacket CO, Kelly SM, Schodel F, et al. Safety and immunogenicity
in humans of an attenuated Salmonella typhi vaccine vector strain expressing
plasmid-encoded hepatitis B antigens stabilized by the ASD balanced lethal
system. Infect Immun 65:3381-3385, 1997.
22. Hohmann EL, Oletta CA, Killeen KP, et al. phoP/phoQ-ddeted Salmonella
typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine
in volunteers. J Infect Dis 173:1408-1414, 1996.
23. Ambrosch F, Hirschhl A, Kremsher P, et al. Investigations on the humoral
immune response to oral live typhoid vaccination with strain Ty21a. Munchen
Med Wochenschr 127:775-778, 1985.
24. Lanata CF, Levine MM, Ristori C, et al. Vi serology in detection of
chronic Salmonella typhi carriers in an endemic area. Lancet 2:441-443,
1983.
25. Nolan CM, Feeley JC, White PCJ, et al. Evaluation of a new assay for
Vi antibody in chronic carriers of Salmonella typhi. J Clin Microbiol
12:22-26, 1980.
26. Olitzki A. Causing Organisms and Host's Reactions. In Enteric Fevers.
Basel, S Karger, 1972, pp 430-486.
27. Keitel WA, Bond NL, Zahradnik JM, et al. Clinical and serological
responses following primary and booster immunization with Salmonella typhi
Vi capsular polysaccharide vaccines. Vaccine 12:195-199, 1994.
28. Losonsky GA, Ferreccio C, Kotloff KL, et al. Development and evaluation
of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection
of chronic Salmonella typhi carriers. J Clin Microbiol 25:2266-2269, 1987.
29. Gupta AK, Rao KM. Simultaneous detection of Salmonella typhi Vi antigen
and antibody in serum by counter-immunoelectropho-resis for an early and
rapid diagnosis of typhoid fever. J Immunol Methods 30:349-353, 1979.
30. Ashcroft MT, Morrison-Ritchie J, Nicholson CC, et al. Antibody responses
to vaccination of British Guiana school children with heat-killed-phenolized
and acetone-killed lyophilized vaccines. Am J Hyg 80:221-228, 1964.
31. Klugman KP, Koornhof HJ, Robbins JB, et al. Immunogenicity, efficacy
and serological correlate of protection of Salmonella typhi Vi capsular
polysaccharide vaccine three years after immunization. Vaccine 14:435-438,
1996.
32. Tacket CO, Hone DM, Curtiss RI, et al. Comparison of the safety and
immunogenicity of aroC, aroD and cya, crp Salmonella typhi strains in
adult volunteers. Infect Immun 60:536-541, 1992.
33. Driesens RJ. Effect of glass on pH-dependent stability of typhoid
vaccine. J Clin Microbiol 2:85-88, 1975.
34. Edsall G, Carlson MC, Formal SB, et al. Laboratory tests of typhoid
vaccines within a controlled field study. Bull World Health Organ 20:1017-1032,
1959.
35. Forrest BD. Impairment of immunogenicity of Salmonella typhi Ty21a
due to preexisting cross-reacting intestinal antibodies. J Infect Dis
166:210-212, 1992.
36. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity
of an oral vaccine. Vaccine 8:321-326, 1990.
37. Kantele A. Immune response to prolonged intestinal exposure to antigen.
Scand J Immunol 33:225-229, 1991.
38. Kantele A, Makela PH. Different profiles of the human immune response
to primary and secondary immunization with an oral Salmonella typhi Ty2
la vaccine. Vaccine 9:423-427, 1991.
39. Kantele A, Arvilommi H, Jokinen I. Specific immunoglobulin-secreting
human blood cells after peroral vaccination against Salmonella typhi.
J Infect Dis 153:1126-1131, 1986.
40. Kantele A, Arvilommi H, Kantele JM, et al. Comparison of the human
immune response to live oral, killed oral or killed parenteral Salmonella
typhi Ty21a vaccines. Microb Pathog 10:117-126, 1991.
41. Kantele A, Kantele JM, Arvilommi H, et al. Active immunity is seen
as a reduction in the cell response to oral live vaccine. Vaccine 9:428-431,
1991.
42. Kantele A, Kantele JM, Savilahti E, et al. Homing potentials of circulating
lymphocytes in humans depend on the site of activation: Oral, but not
parenteral, typhoid vaccination induces circulating antibody-secreting
cells that all bear homing receptors directing them to the gut. J Immunol
158:574-579, 1997.
43. Forrest BD. Identification of an intestinal immune response using
peripheral blood lymphocytes. Lancet 1:81-83, 1988.
44. Czerkinsky CC, Prince SJ, Michalek SM, et al. IgA antibody-producing
cells in peripheral blood after ingestion of antigen: Evidence for a common
mucosal immune system in humans. Proc Natl Acad Sci USA 84:2449-2553,
1987.
45. Levine MM, DuPont LH, Hornick RE, et al. Attenuated streptomycin-dependent
Salmonella typhi oral vaccine: Potential deleterious effects of lyophilization.
J Infect Dis 133:424-429, 1976.
46. Woodward WE. Volunteer studies of typhoid fever and vaccines. Trans
R Soc Trop Med Hyg 74:553-556, 1980.
47. Altemeir WA, Bellanti JA, Buescher EL. The IgM response of children
to Salmonella typhosa vaccine.- II. Comparison of amounts of IgM specific
for the somatic, flagellar and Vi antigens. J Immunol 103:924-930, 1969.
48. Chernokhvostova E, Luxemburg KI, Starshinova V, et al. Study on the
production of IgG, IgA, and IgM antibodies to somatic antigens of Salmonella
typhi in humans. Clin Exp Immunol 4:407-421, 1969.
49. Kumar R, Malaviga AN, Murthy RGS, et al. Immunological study of typhoid:
Immunoglobulins, C3, antibodies, and leukocyte migration inhibition in
patients with typhoid fever and TAB-vaccinated individuals. Infect Immun
10:1219-1225, 1974.
50. Lospallato J, Miller W, Dorward B, et al. The formulation of microglobulin
antibodies: I. Studies on adult humans. J Clin Invest 41:1415-1421, 1962.
51. May RP, BarnettJA, SanfordJP. Characterization of the antibody response
to acetone-killed typhoid vaccine. Public Health Rec 82:257-259, 1967.
52. Forrest BD, LaBrooy JT, Dearlove CE, et al. The human humoral immune
response to Salmonella typhi Ty21a. J Infect Dis 163:336-345, 1991.
53. Sarasombath S, Banchm'n N, Sukosol T, et al. Systemic and intestinal
immunities after different typhoid vaccinations. Asian Pac J Allergy Immunol
5:53-61, 1987.
54. Nisini R, Biselli R, Matricardi PM, et al. Clinical and immunological
response to typhoid vaccination with parenteral or oral vaccines in two
groups of 30 recruits. Vaccine 11:582-586, 1993.
55. D'Amelio R, Tagliabue A, Nencioni L, et al. Comparative analysis
of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid
vaccines. Infect Immun 56:2731-2735, 1988.
56. Tagliabue A, Nencioni CA, et al. Cellular immunity against Salmonella
typhi after live oral vaccines. Clin Exp Immunol 52:242-247, 1985.
57. Nath TR, Malaviva AN, Kumar R, et al. A study of the efficacy of typhoid
vaccine in inducing humoral and cell-mediated immune responses in human
volunteers. Clin Exp Immunol 30:38-43, 1977.
58. Rajagopalan P, Kumar R, Malaviya N. A study of humoral and cell-mediated
response following typhoid vaccination in human volunteers. Clin Exp Immunol
47:275-282, 1982.
59. Klugman K, Gilbertson IT, Kornhoff HJ, et al. Protective activity
of Vi polysaccharide vaccine against typhoid fever. Lancet 2:1165-1169,
1987.
60. Forrest BD, Shearman DJC, LaBrooy JT. Specific immune response in
humans following rectal delivery of live typhoid vaccine. Vaccine 8:209-211,
1990.
61. Tagliabue A, Villa L, De Magistiris MT, et al. IgA-driven T-cell-mediated
antibacterial immunity in man after live oral Ty21 a vaccine. J Immunol
137:1504-1510, 1986.
62. Murphy JR, Baqar S, Munoz C, et al. Characteristics of humoral and
cellular immunity to Salmonella typhi in residents of typhoid-endemic
and typhoid-free regions. J Infect Dis 156:1005-1009, 1987.
63. Murphy JR, Wasserman SS, Baqar S, et al. Immunity to Salmonella typhi:
Considerations relevant to measurement of cellular immunity in typhoid-endemic
regions. Clin Exp Immunol 75:228-233, 1989.
64. Sztein MB, Wasserman SS, Tacket CO, et al. Cytokine production patterns
and lymphoproliferative responses in volunteers orally immunized with
attenuated vaccine strains of Salmonella typhi. J Infect Dis 170:1508-1517,
1994.
65. Sztein M, Tanner MK, Polotsky Y, et al. Cytotoxic T lymphocytes after
oral immunization with attenuated vaccine strains of Salmonella typhi
in humans. J Immunol 155:3987-3993, 1995.
66. Yugoslav Typhoid Commission. A controlled field trial of the effectiveness
of phenol and alcohol typhoid vaccines. Bull World Health Organ 26:357-369,
1962.
67. Yugoslav Typhoid Commission. A controlled field trial of the effectiveness
of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines
in Yugoslavia. Bull World Health Organ 30:623-630, 1964.
68. Ashcroft MT, Nicholson CC, Balwant S, et al. A seven-year field trial
of two typhoid vaccines in Guiana. Lancet 2:1056-1060, 1967.
69. Polish Typhoid Committee. Controlled field trial and laboratory studies
on the effectiveness of typhoid vaccines in Poland 1961-64. Bull World
Health Organ 34:211-222, 1966.
70. Polish Typhoid Committee. Evaluation of typhoid vaccines in the laboratory
and in a controlled field trial in Poland. Bull World Health Organ 31:15-27,
1965.
71. Hejfec LB, Salmin LV, Lejtman MZ, et al. A controlled field trial
and laboratory study of five typhoid vaccines in the USSR. Bull World
Health Organ 34:321-339, 1966.
72. Tapa S, Cvjetanovic B. Controlled field trial on the effectiveness
of one and two doses of acetone-inactivated and dried typhoid vaccine.
Bull World Health Organ 52:75-80, 1975.
73. Hefjec LB, Levina LA, Kuz'minova ML, et al. A controlled field trial
to evaluate the protective capacity of a single dose of acetone-killed
agar-grown and heat-killed broth-grown typhoid vaccines. Bull World Health
Organ 40:903-907, 1969.
74. Black RE, Levine MM, Ferreccio C, et al. Efficacy of one or two doses
of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled
field trial. Chilean Typhoid Committee. Vaccine 8:81-84, 1990.
75. Simanjuntak C, Paleologo F, Punjabi N, et al. Oral immunisation against
typhoid fever in Indonesia with Ty21a vaccine. Lancet 338:1055-1059, 1991.
76. Levine MM, Ferreccio C, Cryz S, et al. Comparison of enteric-coated
capsules and liquid formulation of Ty21a typhoid vaccine in randomised
controlled field trial. Lancet 336:891-894, 1990.
77. Wahdan MH, Serie C, Cerisier Y, et al. A controlled field trial of
live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three
year results. J Infect Dis 145:292-296, 1982.
78. Wahdan MH, Serie C, Germanier R, et al. A controlled field trial of
live oral typhoid vaccine Ty21a. Bull World Health Organ 58:469-474, 1980.
79. Hefjec LB. Duration of postvaccination antityphoid immunity according
to the results of strictly controlled field trials. J Hyg Epidemiol Microbiol
Immunol 13:154-165, 1969.
80. Hornick RB, Greisman SE, Woodward TE, et al. Typhoid fever: Pathogenesis
and immunologic control. N Engl J Med 283:686-691, 739-746, 1970.
81. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. Pediatr
Infect Dis J 8:374-381, 1989.
82. Ferreccio C, Levine MM, Rodriguez H, et al. Comparative efficacy of
two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated
capsules. A field trial in an endemic area. J Infect Dis 159:766-769,
1989.
83. Marmion DE, Naylor GRE, Stewart IO. Second attacks of typhoid fever.
J Hyg 53:260-267, 1953.
84. Panchanathan V, Kumar S, Yeap W, Devi S, Ismail R, Sarijan S, Sam
SM, Jusoh Z, Nordin S, Leboulleux D, Pang T. Comparison of safety and
immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell
killed vaccine in Malaysian Air Force recruits. Bull World Health Organ.
2001;79(9):811-7.
85. Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the
Vi capsular polysaccharide. Arch Int Med 1995;155(21): 2293-9.
86. Keddy KH, Klugman KP, Hansford FC, Blondeau C, Bouveret-Le Cam N.
Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide
vaccine in South African school children 10 years after immunization.
Vaccine 1999;17(2):110-3.
87. Acharya IL, Lowe Ch, Thapa R, et al. Prevention of typhoid fever in
Nepal with the Vi capsular polysaccharide of Salmonella typhi. New Eng
J Med 1987;317(18):1101-4.
88. Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M. Typhim ViTM
vaccine against typhoid fever: a clinical trial in Kenya. East Afr Med
J 1995;72(3):162-4.
89. Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide
vaccine against typhoid fever in south western China. Bull World Health
Org 2001;79(7):625-31.
90. Cryz SJ, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and
immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi
Ty21a)-Cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.
Infect Immun 1995;63(4):1336-9.
91. Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella
typhi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis
1999;18(9):609-20.
92. Tacket CO, Levine MM, Robbins JB.Persistence of antibody titres three
years after vaccination with Vi polysaccharide vaccine against typhoid
fever. Vaccine. 1988 Aug;6(4):307-8.
93. Tacket CO, Ferreccio C, Robbins JB, Tsai CM, Schulz D, Cadoz M, Goudeau
A, Levine MM.Safety and immunogenicity of two Salmonella typhi Vi capsular
polysaccharide vaccines. J Infect Dis. 1986 Aug;154(2):342-5.
94. Arnold WS, Harcus AW, St Clair Roberts J, Ward AE.Experience with
Vi typhoid capsular polysaccharide vaccine in the U.K.,J Infect. 1992
Jul;25(1):63-6.
95. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz
M, Schulz D, Armand J, Bryla DA, Trollfors B. Prevention of typhoid fever
in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary
report. N Engl J Med. 1987 Oct 29;317(18):1101-4.
96. Registrační dokumentace Pasteur Merieux; Monografie Typhim Sanofi
Pasteur
97. 7th Canadian immunization Guide, National Advisory Committee on Immunization
(NACI),2006
98. Wolfe MS. Precautions with oral live typhoid (Ty 21a) vaccine (letter).
Lancet 1990;336:631-2.
99. Brachman PS, Metchock B, Kozarsky PE. Effects of antimalarial chemoprophylactic
agents on the viability of the Ty21a typhoid vaccine strain (letter).
Clin Infect Dis 1992;15:1057-8.
100. Horowitz H, Carbonaro CA. Inhibition of the Salmonella-typhi oral
vaccine strain, Ty21a, by mefloquine and chloroquine (letter). J Infect
Dis 1992;166:1462-4.
101. Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer
R, Lell B, Que JU, Miller GB, Kremsner PG. Efficacy of atovaquone/proguanil
for malaria prophylaxis in children and its effect on the immunogenicity
of live oral typhoid and cholera vaccines. Clin Infect Dis. 2002 Nov 15;35(10):1147-54.
102. Caumes E.: Health and Travel, Aventis Pasteur, 2000
103. Taylor DN, Pollard RA, Blake PA.. Typhoid in the United States and
the risk to the international traveler. J Infect Dis. 1983 Sep;148(3):599-602.
|